Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)

Glioblastoma Clinical Trial

Official title:

SCH 52365 Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00684567
• Other study ID #: P04661
• Secondary ID: JPC-05-351-22
• Status: Completed
• Phase: Phase 2
• First received: May 22, 2008
• Last updated: January 19, 2015
• Start date: September 2005
• Est. completion date: October 2007

Study information

• Verified date: January 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Pharmaceuticals and Medical Devices Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of combination therapy of radiotherapy and temozolomide ("concomitant radiotherapy phase"), and then temozolomide monotherapy ("monotherapy phase"), in patients with newly diagnosed glioblastoma multiforme. Progression free survival and response rate will also be calculated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: October 2007
• Est. primary completion date: October 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Histopathologically confirmed newly diagnosed glioblastoma multiforme with WHO grade IV.

• Histological diagnosis must be made locally after biopsy or neurosurgical tumor resection.

• Four or more unstained tissue sections or a paraffin block must be provided to the Pathological Judgment Committee as tissue specimens.

• Initial surgery/biopsy at diagnosis performed <=6 weeks (42 days) prior to treatment with temozolomide.

• Age: >=18 and <=70 years.

• ECOG performance status <=2.

• Stable, non-increasing dose of corticosteroids over the 14 days prior to treatment with temozolomide.

• No prior chemotherapy or radiotherapy.

• Laboratory test values obtained within 14 days before initiation of administration of temozolomide must satisfy the following criteria:

• absolute neutrophil count >= 1500/mm^3;

• platelet count >= 100,000/mm^3;

• serum creatinine <=1.5 times the upper limit of laboratory normal;

• total bilirubin <=1.5 times the upper limit of laboratory normal;

• glutamic oxaloacetic transaminase or glutamic pyruvic transaminase <2.5 times the upper limit of laboratory normal;

• alkaline phosphatase < 2.5 times the upper limit of laboratory normal.

• Absence of pathological conditions that interfere with taking oral drugs.

• Contraception during the study period (from informed consent to the day of the last observation/examination of this study) is required in sexually active, potentially fertile patients, regardless of sex, under the supervision of the investigator or sub-investigator.

• The investigator and/or subinvestigator must judge that life expectancy is 12 weeks or more.

• Patients may be included regardless of sex or inpatient/outpatient.

Exclusion Criteria:

• Extensively disseminated glioblastoma multiforme.

• Severe disorders in the heart, liver, kidney, blood, etc.

• Presence of previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-situ of the cervix and non melanoma skin cancer.

• Women who are pregnant or lactating.

• Women who may be pregnant or who could become pregnant and do not adopt contraception method(s).

• Participation in another clinical study within 6 weeks prior to the initiation of administration of temozolomide.

• Subjects who the investigator and/or subinvestigator judged inappropriate to participate in the study.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glioblastoma

Intervention

Radiation:
• Radiotherapy
Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.

Drug:
• Temozolomide
During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events With an Incidence of Greater Than or Equal to 20%	Safety was assessed from the start of administration during the concomitant radiotherapy phase until 30 days after the completion of administration of monotherapy. Adverse events were classified under the system organ class using MedDRA-J Version 11.0.	until 30 days after the completion of administration of monotherapy	Yes
Primary	Adverse Drug Reactions With an Incidence of Greater Than or Equal to 20%	Safety was assessed from the start of administration during the concomitant radiotherapy phase until 30 days after the completion of administration of monotherapy.	until 30 days after the completion of administration of monotherapy	Yes
Primary	Abnormal Changes in Laboratory Test Values With an Incidence of Greater Than or Equal to 20%	Safety was assessed from the start of administration during the concomitant radiotherapy phase until 30 days after the completion of administration of monotherapy.	until 30 days after the completion of administration of monotherapy	Yes
Secondary	Number of Participants With Progression Free Survival (PFS) for 1 Year	Administration of SCH 52365 was continued until progression was observed (progression was judged by the investigator based on MRI and clinical symptoms).	1 year after the start of admininstration in the concomitant radiotherapy phase	No
Secondary	Number of Participants With a Response (Complete Response [CR] + Partial Response [PR]) in Terms of Overall Tumor Response	CR = measurable lesion disappeared.; PR = total sum of lesions measurable in bidimension decreased by 50% or more on whole and no secondary progression attributable to tumor was noted. No onset of new lesion.	1 year after the start of administration in the concomitant radiotherapy phase	No